study group (24 patients = intervention) received intervention for 3-daysCetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8.

control group (24 patients) did not receive 3-daysCetrorelix Acetate (no intervention). Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8.

Cetrotide

no Cetrotide

Total

Sex: Female, Male

Race (NIH/OMB)

Region of Enrollment

Serum E2 levels (Serum E2 level in picograms/ml) were evaluated daily.

Daily Serum E2 Levels

MOD (maximal ovarian diameter in mm) were evaluated daily.

Daily Maximal Ovarian Diameter

-All patients were clinically evaluated for the presence of abdominal pain and if present was graduated using a numerical pain visual analogue scale (VAS) with 0 means no pain and 10 means severe intolerable pain .

study group (24 patients = intervention) received intervention for 3-days Cetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8.

Daily Numerical Pain Visual Analogue Scale Score

Blood samples were obtained under complete aseptic condition for determination of hematocrits value (Ht%)

Daily Hematocrits Value

-US detected severity grades of ascites determined at Day -0, Day -3 and Day -8.

Ultrasound Detected Severity Grades of Ascites From Days 0-8

Daily Total Leucocytic Count

-severity grades of gastrointestinal manifestations determined at Day -0,Day -3 and Day -6.

Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy

study group (24 patients = intervention) received intervention for 3-daysCetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD(maximal ovarian diameter) were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8.

Overall Study

dr khalid M Salama

Infertility

study group received 3-day Cetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites control (24 patients) did not receive Cetrorelix Acetate. Grading were re-evaluated on Day-3, 6 and 8.

Cetrorelix

Benha university hospitalا

Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome

Sequential E2 Levels Not Ovarian Maximal Diameter Estimates Were Correlated With Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome

hydrothorax/լուծ

Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome

Բժշկական դեղաբույսերի ամենալավ տվյալների շտեմարանը, որին աջակցում է գիտությունը